Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Holding FATE?
Track your performance easily
See the Price Targets and Ratings of:
FATE Analyst Ratings
Hold
3 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
FATE Stock 12 Month Forecast
Average Price Target
$5.44
▲(164.08% Upside)
| Highest Price Target$10.00 | Average Price Target$5.44 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
Assigned
11/19/24
Leerink Partners
Reiterated
11/19/24
TD Cowen
Reiterated
11/18/24
Bank of America Securities
Upgraded
11/18/24
Oppenheimer
Reiterated
11/18/24
Stifel Nicolaus
Assigned
11/18/24
Needham
Reiterated
11/18/24
Wells Fargo
Reiterated
11/13/24
Morgan Stanley
Reiterated
11/13/24
Piper Sandler
Reiterated
11/13/24
Robert W. Baird
$5
Hold
142.72%
Upside
Reiterated
11/13/24
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Fate Therapeutics (NASDAQ: FATE)
BMO Capital
$6→$5
Hold
142.72%
Upside
Reiterated
11/12/24
Conservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive Edge
H.C. Wainwright
$5
Hold
142.72%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Wedbush
$5
Hold
142.72%
Upside
Reiterated
08/14/24
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Citi
$10
Buy
385.44%
Upside
Reiterated
05/15/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), Acumen Pharmaceuticals (NASDAQ: ABOS) and DENTSPLY SIRONA (NASDAQ: XRAY)
Best Analysts Covering Fate Therapeutics
Which Analyst Should I Follow If I Want to Buy FATE and Sell After:
1 Month
xxx
Success Rate
6/14 ratings generated profit
Average Return
+1.61%
assigned a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +1.61% per trade.
3 Months
xxx
Success Rate
6/14 ratings generated profit
Average Return
+0.17%
assigned a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +0.17% per trade.
1 Year
Success Rate
4/14 ratings generated profit
Average Return
-12.22%
assigned a buy rating 3 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -12.22% per trade.
2 Years
xxx
Success Rate
4/26 ratings generated profit
Average Return
-47.59%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -47.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
FATE Analyst Recommendation Trends
Rating
Apr 24
May 24
Jun 24
Aug 24
Nov 24
Strong Buy
1
4
5
6
6
Buy
5
2
1
2
3
Hold
12
13
12
19
21
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
18
27
30
Each month's total comprises the sum of three months' worth of ratings.
FATE Financial Forecast
FATE Stock Forecast FAQ
What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is $5.44.
What is FATE’s upside potential, based on the analysts’ average price target?
Fate Therapeutics has 164.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FATE a Buy, Sell or Hold?
Fate Therapeutics has a consensus rating of Hold which is based on 3 buy ratings, 10 hold ratings and 0 sell ratings.
What is Fate Therapeutics’s price target?
The average price target for Fate Therapeutics is $5.44. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $3.00. The average price target represents 164.08% Increase from the current price of $2.06.
The highest analyst price target is $10.00 ,the lowest forecast is $3.00. The average price target represents 164.08% Increase from the current price of $2.06.
What do analysts say about Fate Therapeutics?
Fate Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of FATE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.